이 페이지는 자동 번역되었으며 번역의 정확성을 보장하지 않습니다. 참조하십시오 영문판 원본 텍스트의 경우.

Pazopanib Versus Placebo in Patients With Soft Tissue Sarcoma Whose Disease Has Progressed During or Following Prior Therapy (PALETTE)

2013년 8월 15일 업데이트: GlaxoSmithKline

A Randomized Double Blind Phase III Trial of Pazopanib Versus Placebo in Patients With Soft Tissue Sarcoma Whose Disease Has Progressed During or Following Prior Therapy

A randomized double blind phase III trial of Pazopanib versus placebo in patients with soft tissue sarcoma whose disease has progressed during or following prior therapy

연구 개요

상태

완전한

연구 유형

중재적

등록 (실제)

369

단계

  • 3단계

연락처 및 위치

이 섹션에서는 연구를 수행하는 사람들의 연락처 정보와 이 연구가 수행되는 장소에 대한 정보를 제공합니다.

연구 장소

      • Amsterdam, 네덜란드, 1066 CX
        • GSK Investigational Site
      • Groningen, 네덜란드, 9713 GZ
        • GSK Investigational Site
      • Leiden, 네덜란드, 2300 RC
        • GSK Investigational Site
      • Nijmegen, 네덜란드, 6525 GA
        • GSK Investigational Site
      • Rotterdam, 네덜란드, 3075 EA
        • GSK Investigational Site
      • Daegu, 대한민국, 705-717
        • GSK Investigational Site
      • Goyang-si, Gyeonggi-do, 대한민국, 410-769
        • GSK Investigational Site
      • Seoul, 대한민국, 120-752
        • GSK Investigational Site
      • Seoul, 대한민국, 138-736
        • GSK Investigational Site
      • Seoul, 대한민국, 110-744
        • GSK Investigational Site
      • Seoul, 대한민국, 135-710
        • GSK Investigational Site
      • Herlev, 덴마크, DK-2730
        • GSK Investigational Site
    • Baden-Wuerttemberg
      • Heidelberg, Baden-Wuerttemberg, 독일, 69120
        • GSK Investigational Site
      • Mannheim, Baden-Wuerttemberg, 독일, 68167
        • GSK Investigational Site
    • Brandenburg
      • Bad Saarow, Brandenburg, 독일, 15526
        • GSK Investigational Site
    • Hessen
      • Frankfurt, Hessen, 독일, 60590
        • GSK Investigational Site
    • Niedersachsen
      • Hannover, Niedersachsen, 독일, 30625
        • GSK Investigational Site
    • Nordrhein-Westfalen
      • Essen, Nordrhein-Westfalen, 독일, 45122
        • GSK Investigational Site
      • Koeln, Nordrhein-Westfalen, 독일, 50937
        • GSK Investigational Site
    • Sachsen
      • Dresden, Sachsen, 독일, 01307
        • GSK Investigational Site
    • Alabama
      • Birmingham, Alabama, 미국, 35243
        • GSK Investigational Site
    • California
      • Los Angeles, California, 미국, 90048
        • GSK Investigational Site
      • Orange, California, 미국, 92868
        • GSK Investigational Site
      • Santa Monica, California, 미국, 90403
        • GSK Investigational Site
    • Illinois
      • Chicago, Illinois, 미국, 60657
        • GSK Investigational Site
    • Massachusetts
      • Boston, Massachusetts, 미국, 02114
        • GSK Investigational Site
      • Boston, Massachusetts, 미국, 02215
        • GSK Investigational Site
    • Minnesota
      • Minneapolis, Minnesota, 미국, 55455
        • GSK Investigational Site
    • Ohio
      • Clevand, Ohio, 미국, 44106
        • GSK Investigational Site
    • Pennsylvania
      • Philadelphia, Pennsylvania, 미국, 19106
        • GSK Investigational Site
      • Brussels, 벨기에, 1000
        • GSK Investigational Site
      • Brussels, 벨기에, 1200
        • GSK Investigational Site
      • Gent, 벨기에, 9000
        • GSK Investigational Site
      • Leuven, 벨기에, 3000
        • GSK Investigational Site
      • Liège, 벨기에, 4000
        • GSK Investigational Site
      • Göteborg, 스웨덴, SE413 45
        • GSK Investigational Site
      • Linköping, 스웨덴, SE-581 85
        • GSK Investigational Site
      • Lund, 스웨덴, SE-221 85
        • GSK Investigational Site
      • Umeå, 스웨덴, SE-901 85
        • GSK Investigational Site
      • Uppsala, 스웨덴, SE-751 85
        • GSK Investigational Site
      • Madrid, 스페인, 28041
        • GSK Investigational Site
      • Madrid, 스페인, 28040
        • GSK Investigational Site
      • Palma de Mallorca, 스페인, 07010
        • GSK Investigational Site
      • Valencia, 스페인, 46009
        • GSK Investigational Site
      • Glasgow, 영국, G12 0YN
        • GSK Investigational Site
      • Leeds, 영국, LS9 7TF
        • GSK Investigational Site
      • London, 영국, SW3 6JJ
        • GSK Investigational Site
      • Nottingham, 영국, NG5 1PB
        • GSK Investigational Site
      • Sheffield, 영국, S10 2SJ
        • GSK Investigational Site
    • Lancashire
      • Manchester, Lancashire, 영국, M20 4BX
        • GSK Investigational Site
    • Campania
      • Napoli, Campania, 이탈리아, 80131
        • GSK Investigational Site
    • Lazio
      • Roma, Lazio, 이탈리아, 00144
        • GSK Investigational Site
    • Lombardia
      • Milano, Lombardia, 이탈리아, 20133
        • GSK Investigational Site
      • Milano, Lombardia, 이탈리아, 20162
        • GSK Investigational Site
      • Rozzano (MI), Lombardia, 이탈리아, 20089
        • GSK Investigational Site
    • Piemonte
      • Candiolo (TO), Piemonte, 이탈리아, 10060
        • GSK Investigational Site
      • Torino, Piemonte, 이탈리아, 10153
        • GSK Investigational Site
    • Umbria
      • Terni, Umbria, 이탈리아, 05100
        • GSK Investigational Site
      • Aichi, 일본, 464-8681
        • GSK Investigational Site
      • Chiba, 일본, 260-8717
        • GSK Investigational Site
      • Fukuoka, 일본, 811-1395
        • GSK Investigational Site
      • Hokkaido, 일본, 003-0804
        • GSK Investigational Site
      • Mie, 일본, 514-8507
        • GSK Investigational Site
      • Okayama, 일본, 700-8558
        • GSK Investigational Site
      • Osaka, 일본, 540-0006
        • GSK Investigational Site
      • Osaka, 일본, 537-8511
        • GSK Investigational Site
      • Tokyo, 일본, 104-0045
        • GSK Investigational Site
      • Bordeaux cedex, 프랑스, 33076
        • GSK Investigational Site
      • Lille, 프랑스, 59020
        • GSK Investigational Site
      • Lyon Cedex 08, 프랑스, 69373
        • GSK Investigational Site
      • Marseille cedex 5, 프랑스, 13385
        • GSK Investigational Site
      • Paris Cedex 5, 프랑스, 75248
        • GSK Investigational Site
      • Saint-Priest en Jarez, 프랑스, 42271
        • GSK Investigational Site
      • Vandoeuvre-Les-Nancy, 프랑스, 54511
        • GSK Investigational Site
      • Villejuif, 프랑스, 94805
        • GSK Investigational Site
    • New South Wales
      • Randwick, New South Wales, 호주, 2031
        • GSK Investigational Site
    • Queensland
      • Woolloongabba, Queensland, 호주, 4102
        • GSK Investigational Site
    • South Australia
      • Kurralta Park, South Australia, 호주, 5037
        • GSK Investigational Site
    • Tasmania
      • Hobart, Tasmania, 호주, 7000
        • GSK Investigational Site
    • Victoria
      • Box Hill, Victoria, 호주, 3128
        • GSK Investigational Site
    • Western Australia
      • Nedlands, Western Australia, 호주, 6009
        • GSK Investigational Site

참여기준

연구원은 적격성 기준이라는 특정 설명에 맞는 사람을 찾습니다. 이러한 기준의 몇 가지 예는 개인의 일반적인 건강 상태 또는 이전 치료입니다.

자격 기준

공부할 수 있는 나이

18년 이상 (성인, 고령자)

건강한 자원 봉사자를 받아들입니다

아니

연구 대상 성별

모두

설명

Inclusion/Exclusion Criteria:

  • High or intermediate grade of soft tissue sarcoma; Low grade tumours allowed provided there is disease progression.
  • Metastatic and measurable disease (RECIST);
  • Subjects can have received maximum of 4 prior lines of systemic therapies (including up to 2 combination regimens) for advanced disease. (Neo) adjuvant/maintenance treatments are not counted for this criterion;
  • Last dose of prior therapy can be given upto 14 days prior to start of study if all ongoing toxicity from prior anticancer therapy are grade 1 or resolved (except alopecia).
  • Must have failed anthracycline-based therapy and available standard chemotherapies at the treating institution except if medically contraindicated or refused by patient;
  • No treatment with anti-angiogenesis inhibitors;
  • Age > 18 years
  • WHO PS 0-1;
  • No leptomeningeal or brain metastases, normal bone marrow, liver, renal and cardiac functions;
  • No prior history of malignancies other than sarcoma (except for basal cell or squamous cell carcinoma of the skin or carcinoma in-situ of the cervix or breast or the patient has been free of any other malignancies for > 3 years)
  • Adequate bone marrow function; adequate blood clotting results; adequate hepatic and renal function;
  • No poorly controlled hypertension;
  • Clinically normal cardiac function;
  • No clinically significant gastrointestinal abnormalities including malabsorption syndrome, major resection of the stomach or small bowel that could affect the absorption of study drug, active peptic ulcer disease, inflammatory bowel disease, ulcerative colitis, or other gastrointestinal conditions with increased risk of perforation, history of abdominal fistula, gastrointestinal perforation, or intra-abdominal abscess within 28 days prior to beginning study treatment.
  • No cerebrovascular accidents 1
  • No transient ischemic attack, deep vein thrombosis or pulmonary embolism within past six months;
  • No active bleeding or bleeding diathesis;
  • No hemoptysis within six weeks of study drug;
  • No major surgery or trauma within 28 days of therapy treatment;
  • Concomitant medication restriction;
  • No known immediate or delayed hypersensitivity reaction or idiosyncrasy to drugs chemically related to pazopanib
  • Ability to swallow & retain oral medication
  • Adequate contraception must be used;
  • No Psychological familial, sociological or geographical condition potentially hampering compliance with the study protocol and follow-up schedule; those conditions should be assessed with the patient before randomization in the trial.

공부 계획

이 섹션에서는 연구 설계 방법과 연구가 측정하는 내용을 포함하여 연구 계획에 대한 세부 정보를 제공합니다.

연구는 어떻게 설계됩니까?

디자인 세부사항

  • 주 목적: 치료
  • 할당: 무작위
  • 중재 모델: 병렬 할당
  • 마스킹: 네 배로

무기와 개입

참가자 그룹 / 팔
개입 / 치료
위약 비교기: PLACEBO
matching placebo 800 mg once daily orally
matching placebo 800 mg once daily orally
실험적: PAZOPANIB
800 mg once daily orally
800 mg once daily orally

연구는 무엇을 측정합니까?

주요 결과 측정

결과 측정
측정값 설명
기간
Progression-free Survival (PFS)
기간: From the date of randomization until the date of the first documented radiological progression or date of death from any cause, whichever came first (assessed for an average of 10 months)
PFS was defined as the time interval between the date of randomization and the earliest date of either disease progression or death due to any cause. The diagnosis of progression was based on tumor measurements, according to Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.0 criteria, by independent radiologic assessment. The Kaplan-Meier method was used for PFS estimates.
From the date of randomization until the date of the first documented radiological progression or date of death from any cause, whichever came first (assessed for an average of 10 months)

2차 결과 측정

결과 측정
측정값 설명
기간
Overall Survival (OS)
기간: From the date of randomization until 215 deaths (assessed for an average of 12 months)
OS was defined as the time from the date of randomization to the date of death due to any cause. The length of this interval was calculated as the date of death minus the date of randomization plus 1 day. Participants who were alive at the time of analysis were censored at the date of last follow-up. The interim OS analysis was conducted when 215 (77 percent [%]) of the 279 required death events had occurred in the study. The Kaplan-Meier method was used for OS estimates.
From the date of randomization until 215 deaths (assessed for an average of 12 months)
Number of Participants in the Indicated Categories for Overall Response Assessed by an Independent Radiologist and the Investigator
기간: From the start of treatment until disease progression (assessed for an average of 10 months)
Overall response is defined as the number of participants who had a complete response (CR) or a partial response (PR). According to RECIST, Version 1.0: CR, disappearance of all lesions; PR, a >=30% decrease in the sum of the longest dimensions (LD) of the target lesions (TLs) taking as a reference the baseline sum LD; Progressive disease (PD), a >=20% increase in the sum of the LD of TLs, or the appearance of >=1 new lesion; Stable Disease (SD), neither PR nor PD, persistence of >=1 non-TL. Participants with no follow-up radiological disease assessment were categorized as not evaluable (NE).
From the start of treatment until disease progression (assessed for an average of 10 months)
Time to Response Assessed by an Independent Radiologist and the Investigator
기간: From the date of randomization until the date of the first documented evidence of CR or PR (assessed for an average of 10 months)
Time to response was defined as the time from the date of randomization until the date of first documented evidence of CR or PR (whichever status was recorded first). The Kaplan-Meier method was used for time to response estimates.
From the date of randomization until the date of the first documented evidence of CR or PR (assessed for an average of 10 months)
Duration of Response Assessed by the Independent Radiologist and the Investigator
기간: From the date of randomization until the date of the first documented evidence of CR or PR (assessed for an average of 10 months)
Duration of response was defined as the time from the date of the first documented evidence of CR or PR until the date of either the first documented sign of PD or death due to any cause. Participants who neither died nor progressed were censored at the date of the last adequate radiologic assessment. The Kaplan-Meier method was used for duration of response estimates.
From the date of randomization until the date of the first documented evidence of CR or PR (assessed for an average of 10 months)
PFS in the Indicated Histology Subgroups of Soft Tissue Sarcoma (STS)
기간: From the date of randomization until the date of the first documented progression or the date of death from any cause, whichever came first (assessed for an average of 10 months)
PFS was defined as the time interval between the date of randomization and the earliest date of either disease progression or death due to any cause. Participants were analyzed for PFS in histology subgroups of STS (as per the World Health Organization [WHO] classification, 2008): leiomyosarcoma (malignant cancer of smooth muscle), synovial sarcoma (cancer near the joints of the arm or leg), and other STS (without the tumor type of leiomyosarcoma or synovial sarcoma), based on independent review.The Kaplan-Meier method was used for PFS estimates.
From the date of randomization until the date of the first documented progression or the date of death from any cause, whichever came first (assessed for an average of 10 months)
Change From Baseline in Systolic Blood Pressure (SBP) and Diastolic Blood Pressure (DBP)
기간: Baseline, Day 8, Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52, 56, 60, 64, 68, 72, 76, 80, 88, 96, and 104
Change from baseline in on-therapy SBP and DBP was calculated as the values at the indicated time points (Day 8 and Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52, 56, 60, 64, 68, 72, 76, 80, 88, 96, and 104) minus the value at baseline.
Baseline, Day 8, Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52, 56, 60, 64, 68, 72, 76, 80, 88, 96, and 104
Change From Baseline in Heart Rate
기간: Baseline, Day 8, Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52, 56, 60, 64, 68, 72, 76, 80, 88, 96, and 104
Change from baseline in on-therapy heart rate was calculated as the value at the indicated time points (Day 8 and Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52, 56, 60, 64, 68, 72, 76, 80, 88, 96, and 104) minus the value at baseline.
Baseline, Day 8, Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52, 56, 60, 64, 68, 72, 76, 80, 88, 96, and 104
Number of Participants With the Indicated Grade Shifts From Baseline Grade for Hemoglobin Level, Lymphocyte Count, White Blood Cell Count, Neutrophil Count, and Platelet Count
기간: From baseline (Day 1) until study drug discontinuation or end of treatment (assessed for an average of 20 weeks)
Shifts in hematology values by grade were summarized based on the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE Version 3.0). Grade refers to the severity of the AE. The CTCAE Version 3.0 displays Grades 1 through 5 with unique clinical descriptions of severity for each AE based on this general guideline. Participants with a missing baseline grade were assumed to have a baseline Grade of 0. Any increase in grade from baseline and shifts to Grade 3 (severe AE) and 4 (life-threatening or disabling AE) at any point in the study after baseline are reported.
From baseline (Day 1) until study drug discontinuation or end of treatment (assessed for an average of 20 weeks)
Number of Participants With the Indicated Grade Shifts From Baseline Grade for Alkaline Phosphatase, Alanine Aminotransferase, Aspartate Aminotransferase, Albumin, Creatinine, Hyper/Hypoglycemia, Hyper/Hypokalemia, Hyper/Hyponatremia, and Total Bilirubin
기간: From baseline (Day 1) until study drug discontinuation or end of treatment (assessed for an average of 20 weeks)
Shifts in clinical chemistry values by grade were summarized based on the NCI CTCAE Version 3.0. Participants with a missing baseline grade were assumed to have a baseline Grade of 0. Any increase in grade from baseline and shifts to Grade 3 and 4 at any point in the study after baseline are reported. alkaline phosphatase, ALKP; alanine aminotransferase, ALT; aspartate aminotransferase, AST. Hyper/hypoglycemia refers to high/low glucose; hyper/hypokalemia refers to high/low potassium; hyper/hyponatremia refers to high/low sodium.
From baseline (Day 1) until study drug discontinuation or end of treatment (assessed for an average of 20 weeks)
Number of Participants With the Indicated Absolute Percent Change From Baseline (BL) in Left Ventricular Ejection Fraction (LVEF) at Any Time Post-BL (Worst Case On-therapy)
기간: Baseline (within 14 days of the first dose of study drug) and any time post-baseline until study drug discontinuation or end of treatment (assessed for an average of 20 weeks)
LVEF is the measurement of how much blood is being pumped out of the left ventricle of the heart (the main pumping chamber) with each contraction and is used to determine cardiac function (based on the institutional lower limit of normal [LLN]). LVEF was assessed at BL, Week 12, and every second scheduled visit thereafter until study drug discontinuation and end of treatment or as clinically indicated by using multi-gated acquisition scan (MUGA) or echocardiogram (ECHO). Absolute change from BL was calculated as the on-study value minus the baseline value (LVEF is calculated as a percentage).
Baseline (within 14 days of the first dose of study drug) and any time post-baseline until study drug discontinuation or end of treatment (assessed for an average of 20 weeks)

공동 작업자 및 조사자

여기에서 이 연구와 관련된 사람과 조직을 찾을 수 있습니다.

스폰서

간행물 및 유용한 링크

연구에 대한 정보 입력을 담당하는 사람이 자발적으로 이러한 간행물을 제공합니다. 이것은 연구와 관련된 모든 것에 관한 것일 수 있습니다.

일반 간행물

연구 기록 날짜

이 날짜는 ClinicalTrials.gov에 대한 연구 기록 및 요약 결과 제출의 진행 상황을 추적합니다. 연구 기록 및 보고된 결과는 공개 웹사이트에 게시되기 전에 특정 품질 관리 기준을 충족하는지 확인하기 위해 국립 의학 도서관(NLM)에서 검토합니다.

연구 주요 날짜

연구 시작

2008년 10월 1일

기본 완료 (실제)

2010년 11월 1일

연구 완료 (실제)

2012년 12월 1일

연구 등록 날짜

최초 제출

2008년 9월 12일

QC 기준을 충족하는 최초 제출

2008년 9월 15일

처음 게시됨 (추정)

2008년 9월 16일

연구 기록 업데이트

마지막 업데이트 게시됨 (추정)

2013년 8월 22일

QC 기준을 충족하는 마지막 업데이트 제출

2013년 8월 15일

마지막으로 확인됨

2013년 8월 1일

추가 정보

이 연구와 관련된 용어

이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .

구독하다